
5 interviews. 5 minutes. The asthma data from ATS 2026 your patients will be asking about.

Michael Wechsler, MD, of National Jewish Health.

5 interviews. 5 minutes. The asthma data from ATS 2026 your patients will be asking about.

This interview highlights phase 3 findings from the SUNRISE study regarding tezepelumab and oral corticosteroid (OCS) reduction in patients with severe, OCS-dependent asthma.